公开(公告)号：US20230233481A1

公开(公告)日：2023-07-27

申请号：US18190416

申请日：2023-03-27

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN

IPC: A61K31/045 ,  A61P35/00 ,  A61K9/00 ,  A61K31/4015 ,  A61K31/415 ,  A61K31/4188 ,  A61K31/4745 ,  A61K35/17 ,  A61K39/395 ,  A61K45/06 ,  C07K14/705 ,  C07K16/42

CPC classification number: A61K31/045 ,  A61P35/00 ,  A61K9/0019 ,  A61K9/0043 ,  A61K9/0078 ,  A61K31/4015 ,  A61K31/415 ,  A61K31/4188 ,  A61K31/4745 ,  A61K35/17 ,  A61K39/3955 ,  A61K45/06 ,  C07K14/70503 ,  C07K16/42 ,  A61K2039/505

Abstract: The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier.

公开(公告)号：US20230145207A1

公开(公告)日：2023-05-11

申请号：US18150933

申请日：2023-01-06

Applicant: NEONC TECHNOLOGIES, INC.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish PUPPALI

IPC: A61K31/20 ,  A61K47/55 ,  A61K9/00 ,  A61K31/045 ,  A61K45/06

CPC classification number: A61K31/20 ,  A61K47/55 ,  A61K9/0043 ,  A61K31/045 ,  A61K45/06

Abstract: The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of a perillyl alcohol derivative such as a perillyl alcohol ester, or an isoperillyl alcohol derivative such as an isoperillyl alcohol ester. The derivative may be a perillyl alcohol or an isoperillyl alcohol conjugated with a therapeutic agent such as valproic acid. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

公开(公告)号：US20230043663A1

公开(公告)日：2023-02-09

申请号：US17943567

申请日：2022-09-13

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish Puppali

IPC: C07D487/04 ,  C07D231/12 ,  A61P35/00

Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.

公开(公告)号：US20220054481A1

公开(公告)日：2022-02-24

申请号：US17503760

申请日：2021-10-18

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN

IPC: A61K31/495 ,  C07D231/12 ,  A61K31/4188 ,  A61K47/54 ,  C07B59/00 ,  A61K31/4015 ,  A61K9/00 ,  A61K31/045 ,  A61K31/415 ,  C07D207/26 ,  C07C33/14 ,  C07D487/04 ,  A61K45/06 ,  A61N5/10 ,  A61K31/635 ,  A61K47/55 ,  A61K31/366

Abstract: The present methods treat neurofibromatosis by a administering to a subject perillyl alcohol or iso-perillyl alcohol. The present methods also treat neurofibromatosis by administering to a subject a carbamate of perillyl alcohol, or a carbamate of iso-perillyl alcohol. The perillyl alcohol carbamate may comprise perillyl alcohol conjugated with rolipram or temozolomide.

公开(公告)号：US20210268108A1

公开(公告)日：2021-09-02

申请号：US17306167

申请日：2021-05-03

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish PUPPALI

IPC: A61K45/06 ,  A61K31/4015 ,  A61K9/00 ,  A61K31/415 ,  C07D487/04 ,  C07D231/12 ,  C07D207/26 ,  A61K47/54 ,  A61K47/55

Abstract: The present invention provides for a perillyl alcohol (POH) carbamate, such as POH-Rolipram. The present invention also provides for a method of treating a disease such as cancer, by delivering to a patient a therapeutically effective amount of POH-Rolipram.

公开(公告)号：US20190337884A1

公开(公告)日：2019-11-07

申请号：US16465081

申请日：2017-11-29

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN

IPC: C07C69/716 ,  C07C67/08 ,  A61K35/00

Abstract: NEO218 (3-bromo-2-oxo-propionic acid 4-isopropenyl-cyclohex-1-enylmethyl ester), (see formula 1), is a novel molecule that was generated by covalent fusion of two unrelated agents: 3-bromopyruvate (3-BF; an alkylating agent that Inhibits cancer cell metabolism) and perillyi alcohol (POH; a natural monoterpene with anticancer properties). Methods of synthesizing NBO218, pharmaceutical compositions comprising NBO218 and methods of treating cancer using NBO218 are also disclosed.

公开(公告)号：US20170369408A1

公开(公告)日：2017-12-28

申请号：US15482451

申请日：2017-04-07

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish PUPALLI

IPC: C07C33/14 ,  C07D231/12 ,  A61K47/54 ,  C07D207/26 ,  C07B59/00 ,  A61K45/06 ,  A61K31/495 ,  A61K31/4188 ,  A61K31/415 ,  A61K31/4015 ,  A61K31/045 ,  C07D487/04 ,  A61N5/10 ,  C07C2601/16

CPC classification number: A61K31/495 ,  A61K9/0043 ,  A61K31/045 ,  A61K31/4015 ,  A61K31/415 ,  A61K31/4188 ,  A61K45/06 ,  A61K47/54 ,  A61K47/542 ,  A61K47/543 ,  A61N5/10 ,  C07B59/00 ,  C07B2200/05 ,  C07C33/14 ,  C07C2601/16 ,  C07D207/26 ,  C07D231/12 ,  C07D487/04

Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

公开(公告)号：US20130303807A1

公开(公告)日：2013-11-14

申请号：US13939834

申请日：2013-07-11

Applicant: Neonc Technologies, Inc.

Inventor： Thomas CHEN ,  DANIEL LEVIN ,  SATISH PUPPALI

IPC: C07C29/78

CPC classification number: C07C29/92 ,  A61K31/045 ,  A61K31/4188 ,  A61K45/06 ,  A61N5/10 ,  C07B2200/07 ,  C07C29/78 ,  C07C29/86 ,  C07C29/88 ,  C07C67/14 ,  C07C201/12 ,  C07C201/16 ,  C07C2601/16 ,  C07C33/14 ,  C07C205/57 ,  C07C69/76 ,  C07C69/92

Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

公开(公告)号：US20230248662A1

公开(公告)日：2023-08-10

申请号：US18190643

申请日：2023-03-27

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN

IPC: A61K31/045 ,  A61P35/00 ,  A61K9/00 ,  A61K31/4015 ,  A61K31/415 ,  A61K31/4188 ,  A61K31/4745 ,  A61K35/17 ,  A61K39/395 ,  A61K45/06 ,  C07K14/705 ,  C07K16/42

CPC classification number: A61K31/045 ,  A61P35/00 ,  A61K9/0019 ,  A61K9/0043 ,  A61K9/0078 ,  A61K31/4015 ,  A61K31/415 ,  A61K31/4188 ,  A61K31/4745 ,  A61K35/17 ,  A61K39/3955 ,  A61K45/06 ,  C07K14/70503 ,  C07K16/42 ,  A61K2039/505

Abstract: The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier.

公开(公告)号：US20220378780A1

公开(公告)日：2022-12-01

申请号：US17762878

申请日：2020-09-23

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN ,  Axel SCHÖNTHAL

IPC: A61K31/495 ,  A61K31/415 ,  A61K31/4015 ,  A61K47/54 ,  A61P35/02

Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as a primary cutaneous lymphoma which may be a cutaneous T cell lymphoma (CTCL). The CTCL may be mycosis fungoides, primary cutaneous anaplastic large cell lymphoma (ALCL), or Sezary syndrome. A patient may be administered a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene).